



OPEN ACCESS

Original research

Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic

Daniele Altomare ^{1,2,3} Sara Stampacchia ^{4,5,6} Federica Ribaldi,^{1,2} Szymon Tomczyk,^{1,2} Claire Chevalier,^{1,2} Géraldine Poulain,⁷ Saina Asadi,^{4,5} Bianca Bancila,^{4,5} Moira Marizzoni,^{8,9} Marta Martins,² Aurelien Lathuiliere,^{1,2} Max Scheffler,¹⁰ Nicholas J Ashton,^{11,12,13,14} Henrik Zetterberg ^{11,15,16,17,18} Kaj Blennow,¹⁹ Ilse Kern,²⁰ Miguel Frias,²⁰ Valentina Garibotto,^{4,5} Giovanni B Frisoni^{1,2}

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jnnp-2022-330619>).

For numbered affiliations see end of article.

Correspondence to

Dr Daniele Altomare, University of Brescia, Brescia 25123, Italy; Daniele.Altomare@unibs.it

DA and SS are joint first authors.

Received 25 October 2022

Accepted 28 January 2023

Published Online First 3 April 2023



► <http://dx.doi.org/10.1136/jnnp-2022-330958>



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Altomare D, Stampacchia S, Ribaldi F, et al. *J Neurol Neurosurg Psychiatry* 2023;**94**:420–427.

ABSTRACT

Background The key Alzheimer's disease (AD) biomarkers are traditionally measured with techniques/exams that are either expensive (amyloid-positron emission tomography (PET) and tau-PET), invasive (cerebrospinal fluid A β_{42} and p-tau₁₈₁), or poorly specific (atrophy on MRI and hypometabolism on fluorodeoxyglucose-PET). Recently developed plasma biomarkers could significantly enhance the efficiency of the diagnostic pathway in memory clinics and improve patient care. This study aimed to: (1) confirm the correlations between plasma and traditional AD biomarkers, (2) assess the diagnostic accuracy of plasma biomarkers as compared with traditional biomarkers, and (3) estimate the proportion of traditional exams potentially saved thanks to the use of plasma biomarkers. **Methods** Participants were 200 patients with plasma biomarkers and at least one traditional biomarker collected within 12 months.

Results Overall, plasma biomarkers significantly correlated with biomarkers assessed through traditional techniques: up to $r=0.50$ ($p<0.001$) among amyloid, $r=0.43$ ($p=0.002$) among tau, and $r=-0.23$ ($p=0.001$) among neurodegeneration biomarkers. Moreover, plasma biomarkers showed high accuracy in discriminating the biomarker status (normal or abnormal) determined by using traditional biomarkers: up to area under the curve (AUC)=0.87 for amyloid, AUC=0.82 for tau, and AUC=0.63 for neurodegeneration status. The use of plasma as a gateway to traditional biomarkers using cohort-specific thresholds (with 95% sensitivity and 95% specificity) could save up to 49% of amyloid, 38% of tau, and 16% of neurodegeneration biomarkers.

Conclusion The implementation of plasma biomarkers could save a remarkable proportion of more expensive traditional exams, making the diagnostic workup more cost-effective and improving patient care.

BACKGROUND

According to the first diagnostic criteria of Alzheimer's disease (AD) published in 1984, a definite diagnosis of AD was possible only postmortem, based on histopathological evidence of AD pathology.¹ Since then, increased understanding of AD pathophysiology and technological advancements have favoured the development of new techniques assessing AD biomarkers, allowing to detect

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Plasma biomarkers have become available recently, and evidence on their clinical validity and performance to screen memory clinic patients is not available yet.

WHAT THIS STUDY ADDS

⇒ Plasma biomarkers significantly correlated with traditional biomarkers of Alzheimer's disease, and showed high accuracy discriminating the biomarker status (normal vs abnormal) determined by using traditional biomarkers. The use of plasma as a gateway to traditional biomarkers using cohort-specific thresholds could save up to 49% of traditional exams.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ The implementation of plasma biomarkers could save a remarkable proportion of more expensive traditional exams, making the diagnostic workup more cost-effective and improving patient care.

AD pathology not only in vivo, but also before the onset of clinical symptoms. Thus, AD biomarkers have been progressively introduced into clinical practice and their clinical use is constantly growing, consistently with the most recent diagnostic criteria that acknowledged their key pathophysiological meaning.

AD biomarkers can be grouped into three main categories: 'A' refers to β -amyloid, 'T' to tau, and 'N' to neurodegeneration.² They can be assessed through different techniques such as neuroimaging (ie, MRI and positron emission tomography (PET)), cerebrospinal fluid (CSF), or plasma. Each technique features advantages and disadvantages. Specifically, neuroimaging techniques allow a direct measure of AD biomarkers and provide precious information on their topography, but their information is limited to individual biomarkers (ie, only A, T or N), they are more expensive and might involve small amounts of radiations. CSF analysis is a cheaper and more accessible technique providing information on all ATN (and other) biomarkers at the same time, yet it is an indirect measure, does not

provide information on topography, and is sometimes not well accepted by patients due to its invasive nature. Plasma has the same advantages as CSF, yet its higher accessibility might make possible a large-scale screening for AD in the near future, better selection of patients who should undergo more advanced investigations (eg, neuroimaging), and monitoring of disease progression with more regular repeated sampling.

Some neuroimaging techniques (ie, structural MRI and fluoro-deoxyglucose (FDG)-PET) and CSF measures have been used for clinical purposes for a long time, and their clinical validity is supported by consistent evidence.³ PET tracers allowing to assess amyloid and tau deposition have been recently developed, and preliminary evidence suggests their clinical validity and diagnostic impact.⁴ Therefore, neuroimaging and CSF measures can be considered as traditional techniques/exams assessing AD biomarkers. Differently, plasma biomarkers have become available even more recently,⁵ and evidence regarding their clinical validity is not yet available. However, given the advantages of plasma over neuroimaging and CSF biomarkers, evidence on their clinical validity and their performance to screen memory clinic patients is strongly needed.

The aims of the present study were: (1) to confirm the correlations between plasma and homologous traditional AD biomarkers, (2) to assess the diagnostic accuracy of plasma biomarkers as compared with traditional biomarkers, and (3) to estimate the proportion of traditional exams potentially saved thanks to the use of plasma biomarkers.

METHODS

Participants

Participants were patients previously enrolled at the Memory Centre of the Geneva University Hospitals for whom plasma biomarkers and at least one homologous traditional biomarker collected within 12 months were available. Patients came to the centre because of cognitive complaints and underwent diagnostic workup including clinical and neuropsychological assessments, and biomarker investigations when clinically relevant or as part of research projects.⁶ Patients were classified by cognitive stage (cognitively unimpaired (CU), mild cognitive impairment (MCI), dementia). MCI⁷ and dementia⁸ stages were defined based on their respective clinical diagnostic criteria.

Biomarker classification

Neuroimaging and CSF measures were considered as traditional biomarkers due to the long-standing clinical experience with them.⁹ Neuroimaging, CSF, and plasma biomarkers were

grouped into amyloid, tau, and neurodegeneration categories as follows (table 1).

- ▶ Amyloid: amyloid-PET, CSF $A\beta_{42}$, plasma $A\beta_{42}/A\beta_{40}$, plasma p-tau₁₈₁/ $A\beta_{42}$, and plasma p-tau₂₃₁/ $A\beta_{42}$.
- ▶ Tau: tau-PET, CSF p-tau₁₈₁, plasma p-tau₁₈₁, plasma p-tau₂₃₁, plasma p-tau₁₈₁/ $A\beta_{42}$, and plasma p-tau₂₃₁/ $A\beta_{42}$.
- ▶ Neurodegeneration: structural MRI, FDG-PET, and plasma neurofilament light (NfL). Note that we compared biomarkers measuring different pathophysiological processes associated with neurodegeneration, namely: atrophy, hypometabolism and axonal injury and astroglia, respectively.

We assessed plasma $A\beta_{42}/A\beta_{40}$ as a measure of amyloid consistently with previous studies reporting that this measure identifies amyloid deposition better than $A\beta_{42}$ alone.¹⁰ Moreover, we considered plasma p-tau/ $A\beta_{42}$ as a measure of both amyloid and tau as previous studies suggested that this measure is predictive of both amyloid^{10 11} and tau¹² deposition.

Biomarkers collection, analyses, and assessment

Plasma biomarkers

Plasma samples were collected in EDTA tubes at the Memory Centre of the Geneva University Hospitals, homogeneously kept 2 hours at room temperature before centrifugation (1700 g 15 min), aliquoted as 500 μ L in 1.2 mL polypropylene tubes and stored at -80°C in the local biobank until the time of shipment. Aliquots were shipped under protected conditions and analysed at the Clinical Neurochemistry Laboratory, University of Gothenburg, Sweden. Plasma $A\beta_{42}$, $A\beta_{40}$, and NfL concentrations were measured using commercially available Single molecule array (Simoa)¹³ assays on an HD-X Analyser according to instructions from the kit manufacturer (Quanterix, Billerica, MA), while p-tau₁₈₁¹⁴ and p-tau₂₃₁¹⁵ concentrations were measured using in-house Simoa methods²³¹ developed at the Clinical Neurochemistry Laboratory, University of Gothenburg, Sweden.

Biomarkers concentrations were measured by board-certified laboratory technicians who were blinded to clinical data in two rounds of experiments, using two batches of reagents: values extracted from the second and more comprehensive round were used to assess the main study outcomes, while the first round consisted in the extraction of p-tau₁₈₁ (n=82) and NfL (n=87) values of a subset of participants and was used to assess the test-retest reliability of these plasma measures. Intra-assay coefficients of variation were below 10%.

Table 1 Biomarker classification and comparisons performed in the present study

		Traditional exams				
		Amyloid-PET	Tau-PET	MRI	FDG-PET	CSF
Plasma	$A\beta_{42}$	X				$A\beta_{42}$
	$A\beta_{42}/A\beta_{40}$	X				$A\beta_{42}$
	p-tau ₁₈₁ / $A\beta_{42}$	X	X			$A\beta_{42}$
	p-tau ₂₃₁ / $A\beta_{42}$	X	X			$A\beta_{42}$
	p-tau ₁₈₁		X			p-tau ₁₈₁
	p-tau ₂₃₁		X			p-tau ₁₈₁
	NfL			X	X	

Traditional biomarkers were used both as continuous and dichotomous (normal or abnormal) measures. Continuous measures were Centiloid for amyloid-PET, standardised uptake value ratio (SUVr) for tau-PET and FDG-PET, hippocampal volume for MRI, concentration for CSF. Amyloid-PET positivity: visual reading. CSF $A\beta_{42}$ positivity: <880.5 pg/mL. Tau-PET positivity: Braak stages IV-VI. CSF p-tau₁₈₁ positivity: >80.5 pg/mL. MTA positivity: age-based cut-off. FDG-PET positivity: SUVr <1.21. CSF, cerebrospinal fluid; NfL, neurofilament light; PET, positron emission tomography.

Neuroimaging biomarkers

In the present study, we used both continuous and dichotomous (normal vs abnormal) measures of AD biomarkers assessed using traditional techniques. Detailed information on acquisition protocols is available in a previous publication.⁶

Structural 3T MRI images were acquired. The average of left and right hippocampal volumes (extracted using automated segmentation from FreeSurfer (V.7.0) recon-all tool),¹⁶ adjusted by total intracranial volume, was used as a continuous variable. As a clinically meaningful measure, we used the average medial temporal lobe atrophy scale (MTA) visual score of the left and right hemispheres, and MTA positivity was defined using the age-specific cutoffs that best discriminate between patients with AD dementia and controls (ie, ≥ 1 for patients aged < 65 and ≥ 1.5 for patients aged ≥ 65).¹⁷

Amyloid-PET images were acquired using 18F-florbetapir or 18F-flutemetamol tracers, and tau-PET images were acquired using 18F-Flortaucipir, using standard imaging protocol and reconstructions, previously described in detail¹⁸ and briefly summarized here. 18F-florbetapir images were acquired 50 min after injection of 200 MBq during 15 min; 18F-flutemetamol images were acquired 90 min after injection of 150 MBq, during 20 min; and 18F-flortaucipir images were acquired 75 min after injection of 180 MBq, during 30 min.¹⁸ All acquisitions were performed on Siemens Biograph and Biograph Vision scanners, and reconstructed using a 3D OSEM iterative reconstruction, corrected for randoms, dead time, normalisation, scatter, attenuation, and sensitivity.¹⁸ PET images were processed using an in-house pipeline based on SPM12 (Wellcome Department of Cognitive Neurology, London, UK).¹⁸ FDG-PET images were acquired using 18F-FDG, following the European Association of Nuclear Medicine guidelines.¹⁹ PET images were processed using an in-house code as described in a previous publication.¹⁸

As in our cohort we used two different amyloid-PET tracers, the standardized uptake value ratio (SUVr) was converted to the Centiloid (CL) scale, according to the Global Alzheimer's Association Interactive Network guidelines,²⁰ and used as a continuous measure. Indeed, as the two tracers have different but strongly correlated uptakes,²¹ their standardisation in a common scale has been proposed to harmonise the results obtained across tracers.²² Amyloid-PET positivity was visually assessed by an expert in nuclear medicine physician (VG, > 15 years of experience in the field) using visual assessment and standard operating procedures approved from the European Medicines Agency.^{23 24}

Global tau-PET SUVr was computed as an average across parahippocampal gyrus, amygdala, mid-occipital cortex, and inferior temporal cortex,²⁵ and used a continuous measure. Tau distribution was determined in each patient by the same expert in nuclear medicine (VG), who visually analysed images in agreement with recently published recommendations,²⁶ describing regions of increased 18F-flortaucipir uptake in the regions corresponding to the pathologically defined Braak stages: medial temporal regions for Braak stages I–III, later temporal regions for Braak stage IV, parietal and frontal lobes for Braak stage V, and sensorimotor areas and visual primary cortex for Braak stage VI (see a previous paper⁴ for a more detailed description). To define tau-PET positivity, visually scored Braak stages 0–III were considered as tau negative, and Braak stages IV–VI as tau positive, in accordance with current knowledge on cognitive impact of tau pathology²⁷ and on detectability of tau pathology with 18F-flortaucipir,²⁸ and consistently with a recent study.²⁹

Global FDG-PET SUVr was extracted from a composite region of five metaROIs: left and right angular gyrus, left and

right temporal cortices, and posterior cingulate.³⁰ FDG-PET positivity was defined based on a previously published cut-off (ie, $SUVr < 1.21$).³¹

CSF biomarkers

CSF samples were collected at the Memory Centre of the Geneva University Hospitals. More information on CSF collection protocol is reported in a previous paper.⁶ CSF A β_{42} (product number 81576) and p-tau₁₈₁ (product number 81574) were analysed using INNOTEST³² assays following the manufacturer's instructions (Fujirebio, Ghent, Belgium) at the Chemistry Laboratory of the Geneva University Hospitals. CSF biomarkers positivity was determined using cohort-specific thresholds (CSF A $\beta_{42} < 880.5$ pg/mL and CSF p-tau₁₈₁ > 80.5 pg/mL).

Test–retest reliability

For a subset of participants, plasma p-tau₁₈₁ and plasma NfL concentrations from the same-day plasma withdrawal were assessed in two different batches of laboratory analyses (see section 'Plasma biomarkers'). Values from the first batch were used to assess the test–retest reliability of plasma p-tau₁₈₁ (n=82) and plasma NfL (n=87).

Statistical analysis

The associations between plasma and traditional biomarkers and the test–retest reliability of plasma biomarkers were assessed by using Pearson's correlation (*r*).

The diagnostic accuracy of plasma biomarkers over amyloid-PET and tau-PET was assessed through the area under the curve (AUC) of the receiver operating characteristics (ROC) using the 'pROC' package in R.³³

To estimate the proportion of traditional exams that could be saved by using plasma biomarkers in clinical practice, we derived from the ROC curves cut-offs with 95% sensitivity or 95% specificity, and then computed the number of scans below and above these cut-offs (ie, true negative + false negative using the 95%-sensitivity cut-off, and true positive + false positive using the 95%-specificity cut-off). For each proportion of saved exams, we computed the 'error rate', that is, the proportion of exams incorrectly saved, consisting of the sum of the false negatives resulting from the 95%-sensitivity cut-off and the false positives resulting from the 95%-specificity cut-off out of the total of the saved exams.

Finally, test–retest reliability was assessed by using Pearson's correlation (*r*) and fold change (using the following formula: (second batch values – first batch values) / first batch values).

All statistical analyses were performed with R, version 4.1.2 (R Foundation for statistical computing, <https://www.r-project.org/>).

RESULTS

Participants

Plasma biomarkers and at least one traditional biomarker were available for 200 patients (82 CU, 99 MCI, 19 dementia). Overall, the level of cognitive impairment and positivity to traditional biomarkers were directly proportional to the cognitive stage severity (table 2). The average time (median \pm IQR) between the collection of plasma and traditional biomarkers was 14 \pm 142 days for amyloid-PET, 14 \pm 127 days for tau-PET, 9 \pm 69 days for CSF, 42 \pm 124 for MRI, and 48 \pm 139 for FDG-PET. Online supplemental table S1 illustrates the demographic and clinical features of each subsample of participants with plasma biomarkers and at least one traditional biomarker.

Table 2 Demographic, clinical, cognitive and biomarker features of participants with biomarkers assessed through plasma and at least one traditional exam (ie, PET, CSF, MRI or FDG-PET)

Demographic and clinical features	Cognitive stage			P value	
	CU	MCI	Dementia		
	n=82	n=99	n=19		
Age, years	71 (12) ^b	73 (10) ^a	76 (8)	0.014	
Gender, males	44% (36)	53% (52)	53% (10)	0.486	
Education, years	16 (5) ^a [2]	14 (6) ^b	12 (4) ^b	<0.001	
MMSE	29 (2) ^a [13]	26 (4) ^b [5]	21 (9) ^c 1	<0.001	
CDR	0.0 (0.0) ^c [27]	0.5 (0.0) ^b [14]	1.0 (0.0) ^a 4	<0.001	
Clock drawing test	10 (1) ^a [11]	9 (2) ^b [8]	6 (3) ^c 2	<0.001	
Three object three places	9 (0) ^a [29]	8 (3) ^b [12]	4 (5) ^c 4	<0.001	
FCSRT—total free recall immediate	29 (8) ^a [17]	18 (7) ^b [29]	13 (3) ^b 13	<0.001	
FCSRT—total recall immediate	47 (3) ^a [17]	40 (9) ^b [30]	35 (8) ^b 14	<0.001	
FCRST—delayed free recall	12 (3) ^a [17]	7 (7) ^b [26]	1 (6) ^b 12	<0.001	
FCSRT—delayed total recall	16 (0) ^a [17]	14 (4) ^b [26]	10 (3) ^b 12	<0.001	
TMT-A	41 (18) ^b [19]	48 (22) ^a [28]	74 (61) ^a 11	<0.001	
TMT-B	90 (46) ^b [19]	124 (63) ^a [35]	152 (20) ^a 14	<0.001	
Digit span—forward	9 (2) ^a [19]	8 (2) ^b [22]	6 (4) ^b 7	<0.001	
Digit span—backward	8 (2) ^a [19]	7 (2) ^b [22]	5 (2) ^b 7	<0.001	
HADS—anxiety	6 (5) [11]	6 (5) [10]	5 (3) 3	0.576	
HADS—depression	3 (4) [11]	4 (5) [10]	4 (7) 3	0.218	
Positivity to traditional exams					
A	Amyloid-PET	28% (11/39) ^b [43]	58% (51/88) ^a [11]	73% (11/15) ^a 4	0.002
	CSF A β_{42}	60% (6/10) [72]	79% (27/34) [65]	86% (6/7) 12	0.367
T	Tau-PET	4% (1/27) ^b [55]	38% (25/66) ^a 33	67% (8/12) ^a 7	<0.001
	CSF p-tau ₁₈₁	70% (7/10) [72]	74% (25/34) 65	86% (6/7) 12	0.746
N	MRI	21% (15/71) [11]	35% (29/84) 15	54% (7/13) 6	0.031*
	FDG-PET	0% (0/6) [76]	2% (1/47) ^b 52	45% (5/11) ^a 8	<0.001

Post hoc comparisons: ^a > ^b > ^c.

Values are medians (IQR) for continuous variables, or percentages (raw numbers) for categorical variables. Statistical analyses: Kruskal-Wallis rank sum test for continuous variables, or test for equality of proportions for categorical variables.

[Number in square brackets]: number of missing data.

*No pairwise comparison survived the Bonferroni correction.

CDR, Clinical Dementia Rating; CSF, cerebrospinal fluid; CU, cognitively unimpaired; FCSRT, Free and Cued Selective Reminding Test; FDG, 18F-fluorodeoxyglucose; HADS, Hospital Anxiety and Depression Scale; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; PET, Positron Emission Tomography; TMT, Trail Making Test.

Correlation among biomarkers

Among plasma A biomarkers, plasma p-tau₂₃₁/A β_{42} showed the highest correlation with amyloid-PET CL ($r=0.50$, $p<0.001$), and plasma A β_{42} /A β_{40} with CSF A β_{42} ($r=0.42$, $p=0.002$) (online supplemental figure S1). Among plasma T biomarkers, plasma p-tau₂₃₁ showed the highest correlation with tau-PET ($r=0.37$, $p<0.001$), and plasma p-tau₁₈₁ showed the highest correlation with CSF p-tau₁₈₁ ($p=0.43$, $p=0.002$) (online supplemental figure S2). Finally, plasma NfL significantly correlated with hippocampal volume ($p=-0.23$, $p=0.001$) (online supplemental figure S3).

Diagnostic accuracy of plasma biomarkers

When testing the accuracy of plasma A biomarkers (ie, plasma A β_{42} , plasma A β_{42} /A β_{40} , plasma p-tau₁₈₁/A β_{42} and plasma p-tau₂₃₁/A β_{42}) in predicting A status defined using traditional A biomarkers (ie, amyloid-PET or CSF A β_{42}), AUC values ranged from 0.66 (plasma A β_{42}) to 0.83 (plasma p-tau₂₃₁/A β_{42}) when using amyloid-PET as the gold standard, and from 0.69 (plasma A β_{42}) to 0.87 (plasma p-tau₂₃₁/A β_{42}) when using CSF A β_{42} as the gold standard (online supplemental figure S4).

When testing the accuracy of plasma T biomarkers (ie, plasma p-tau₁₈₁, plasma p-tau₂₃₁, plasma p-tau₁₈₁/A β_{42} , and plasma p-tau₂₃₁/A β_{42}) in predicting T status defined using traditional T

biomarkers (ie, tau-PET or CSF p-tau₁₈₁), AUC values ranged from 0.78 (plasma p-tau₁₈₁) to 0.81 (plasma p-tau₂₃₁/A β_{42}) when using tau-PET as the gold standard, and from 0.75 (plasma p-tau₂₃₁) to 0.82 (p-tau₁₈₁/A β_{42}) when using CSF p-tau₁₈₁ as the gold standard (online supplemental figure S4).

When testing the accuracy of plasma N biomarker (ie, plasma NfL) in predicting N status defined using traditional N biomarkers (ie, MTA or FDG-PET), AUC values were 0.58 when using MTA score as the gold standard, and 0.63 when using FDG-PET as the gold standards (online supplemental figure S4).

Traditional exams saved using plasma biomarkers

Figure 1 illustrates the performance of 95%-sensitivity and 95%-specificity plasma biomarkers cutoffs over traditional homologous biomarkers. The estimated proportion of saved amyloid-PET scans ranged from 15% using plasma A β_{42} (error rate: 29%) to 39% using plasma p-tau₂₃₁/A β_{42} (error rate: 11%) (figure 2). The estimated proportion of saved CSF A β_{42} ranged from 27% using plasma A β_{42} (error rate: 7%) to 49% using p-tau₂₃₁/A β_{42} (error rate: 4%) (figure 2). The estimated proportion of saved tau-PET scans ranged from 34% using plasma p-tau₁₈₁ (error rate: 12%) to 38% using plasma p-tau₂₃₁ or p-tau₂₃₁/A β_{42} (error rate: 11%) (figure 2). The estimated proportion of saved CSF p-tau₁₈₁ ranged from 14% using p-tau₂₃₁ (error




Figure 1 Performance of 95%-sensitivity and 95%-specificity plasma biomarkers cutoffs over traditional (A) amyloid (amyloid-PET and CSF Aβ₄₂), (B) tau (tau-PET and CSF p-tau₁₈₁), and (C) neurodegeneration (MRI MTA, FDG-PET) biomarkers. Amyloid-PET positivity: visual reading. CSF Aβ₄₂ positivity: <880.5 pg/mL. Tau-PET positivity: Braak stages IV-VI. CSF p-tau₁₈₁ positivity: >80.5 pg/mL. MTA positivity: age-based cut-off. FDG-PET positivity: SUVr <1.21. One plasma p-tau₁₈₁/Aβ₄₂ value (24.0) and two plasma NfL values (188.1 pg/mL and 260.1 pg/mL) were not displayed to improve data visualisation (but were included in the analyses). CSF, cerebrospinal fluid; CU, cognitively unimpaired; FDG, fluorodeoxyglucose; MCI, mild cognitive impairment; NfL, neurofilament light; PET, positron emission tomography; SUVr, standardised uptake value ratio.

rate: 14%) to 22% using p-tau₁₈₁ (error rate: 9%) (figure 2). The estimated proportion of saved MRI scans was 14% using plasma NfL (error rate: 30%) (figure 2). The estimated proportion of saved FDG-PET scans was 16% using plasma NfL (error rate: 20%) (figure 2).

Test-retest reliability

The test-retest reliability of plasma biomarkers assessed from the same sample but in different batches was good both for plasma p-tau₁₈₁ (r=0.82, p<0.001; fold change: 0.8±0.7) and for plasma NfL (r=0.97, p<0.001; fold change: 0.9±0.2) (online supplemental figure S5).

DISCUSSION

In the present work, we observed that amyloid and tau plasma biomarkers significantly correlated with traditional biomarkers (ie, amyloid-PET, tau-PET, CSF Aβ₄₂ and CSF p-tau₁₈₁), and that correlations between plasma NfL and traditional biomarkers (MRI and FDG-PET) were weaker. Moreover, plasma biomarkers reached an excellent diagnostic accuracy in detecting positivity to traditional amyloid and tau biomarkers (with plasma Aβ₄₂/p-tau ratios showing the best performance), while the diagnostic accuracy in detecting positivity to neurodegeneration biomarkers was overall lower and not acceptable. Finally, we estimated that up to 39% of amyloid-PET, 49% of CSF Aβ₄₂, 38% of tau-PET, 22% of CSF p-tau₁₈₁, 14% of MRI, and 16% of FDG-PET could be saved with a relatively low error rate using plasma biomarkers.

Our results showed that, overall, plasma p-tau (both alone and in combination with Aβ₄₂) showed the best performance both in terms of correlation with traditional biomarkers and of diagnostic accuracy over traditional biomarkers, while Aβ₄₂




Figure 2 Proportion of traditional exams that could be saved by using plasma biomarkers with 95%-sensitivity or 95%-specificity cut-offs. Values indicate the proportion of saved traditional exams and the 'error rate'. The proportion of saved traditional exams was defined as the number of patients identified with the use of plasma biomarkers with 95%-sensitivity and 95%-specificity cut-offs (ie, true negatives+false negatives resulting from the 95%-sensitivity cut-off, and true positives+false positives resulting from the 95%-specificity cut-off) out of the total number of participants with plasma and traditional biomarkers. The 'error rate' is defined as the number of traditional exams incorrectly saved (ie, false negatives resulting from the 95%-sensitivity cut-off+false positive resulting from the 95%-specificity cut-off) out of the total number of the saved traditional exams. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; NfL, neurofilament light; PET, positron emission tomography.

alone and NfL showed weaker associations with and poorer diagnostic accuracy over amyloid and neurodegeneration traditional biomarkers, respectively. Moreover, plasma biomarkers proved to be useful tools to detect the amyloid and tau status of memory clinic patients, while their potential to detect the neurodegeneration status seemed inadequate. This might be due to the non-specific and more heterogeneous nature of neurodegeneration and its imaging markers, while amyloid and tau deposits are more closely related to the presence of specific neurodegenerative diseases such as AD which are associated with plasma biomarkers. Finally, the implementation of plasma biomarkers as screening tools can remarkably reduce the number of traditional exams, as previously shown by Verberk and colleagues in a population of individuals with subjective cognitive decline (−51% of CSF and −54% of amyloid-PET using plasma Aβ₄₂/Aβ₄₀).³⁴

The screening strategy we suggest here could be implemented in clinical practice by performing plasma assessment in patients for whom an investigation of amyloid, tau and neurodegeneration statuses is considered appropriate. Patients with values

below or above the thresholds for a sensitivity and specificity of 95% could be considered classifiable with a relatively high confidence, while others should be addressed for further investigation using traditional biomarkers in an integrated diagnostic approach.³⁵

Before its clinical implementation, however, three main achievements should be fulfilled. (1) The test-retest reliability of the test should be evaluated systematically for all biomarkers and combinations thereof.³⁶ In our sample, we could only evaluate test-retest stability of two biomarkers (p-tau₁₈₁ and NfL), considering only analytical and postanalytical variables. Indeed, the test-retest variability shown here is an underestimation, as we tested twice samples that were collected at the same blood withdrawal, and thus our estimates did not take into account many other variables that can affect plasma biomarkers, such as concomitant medications and physiological and pathological conditions.³⁷ (2) An optimisation of operating procedures and assay reproducibility should be achieved, with a detailed protocol for the handling of plasma AD biomarkers and a cross-validation across laboratories, in analogy with what has been already achieved for CSF markers.^{38,39} This step would be a prerequisite to derive cohort-independent thresholds which would be necessary for a widespread clinical implementation. It is to be expected that different thresholds will be needed for different goals. Indeed, cut-offs might largely vary depending on the purpose (screening vs population enrichment), on the strategy adopted (data-driven from healthy controls or to maximise difference between two populations), and on individual characteristics of the included sample, for example, with different recommendations for different age ranges.⁴⁰ (3) Specific strategies need to be developed to minimise the impact of errors. As mentioned, even selecting conservative thresholds to achieve a sensitivity and specificity of 95%, respectively, the error rates measured here ranged from 4% to 30%. These error rates are, by definition, underestimated as they do not take into account the impact of the observed test-retest variability. It will also be important to develop specific strategies to independently verify the results, for example, testing if the concordance of the clinical hypothesis and the test result might help identifying patients erroneously classified, or estimating the consequences of false negative and false positive results on the basis of disease severity and patient profile.

Limitations

The main limitation of the present study is its retrospective nature. Indeed, the thresholds used here to classify patients were derived from the same cohort on which they were applied. As such, the cut-offs derived in the present study are cohort-specific and should not be used to classify patients from different memory clinics or with different clinical features. Nevertheless, this study should be considered as a demonstration that it is possible to implement plasma biomarkers in clinical practice, and that the use of these might result in a more efficient diagnostic workup. Prospective studies are needed to replicate these results and possibly to provide reliable cut-offs that might be used by other centres or in clinical settings different than specialised memory clinics.

Furthermore, our sample mostly included patients with MCI, as it commonly happens in memory clinic populations,⁴¹ preventing us from drawing conclusions on the individual disease stages. For this reason, we chose not to focus on the individual disease stages, but to consider all patients (irrespective of the clinical stages) as a unique memory clinic sample.

The over-representation of MCI patients allows us to generalise our results to a wider memory clinic population undergoing biomarker testing (as MCI patients are the ones who might benefit the most from biomarker testing³).

Moreover, in the present study, we did not include the mass spectrometry version of plasma biomarkers.

Finally, it is important to underline that the procedures described here include some specificities that might impact their performance. Factors that might lead to an overestimation of the diagnostic accuracy are the fact that the assessment of all experimental samples was performed in the same reference laboratory and based on only one or two analytical batches. One main factor that could instead negatively influence the diagnostic performance is the fact that frozen samples were stored for a variable duration. Nevertheless, the plasma biomarkers examined here all seem to be stable at different storage temperatures and not sensitive to effects of freeze-thawing.⁴²

CONCLUSIONS

Plasma biomarkers were overall concordant with traditional biomarkers, reached an excellent diagnostic accuracy compared with traditional amyloid and tau biomarkers (and a lower accuracy when compared with traditional neurodegeneration biomarkers), and their implementation might save up to 49% of traditional exams with a relatively low error rate.

Author affiliations

¹Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland

²Geneva Memory Center, Geneva University Hospitals, Geneva, Switzerland

³Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

⁴Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, Switzerland

⁵Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospitals, Geneva, Switzerland

⁶Laboratory of Cognitive Neuroscience (LNCO), Center of Neuroprosthetics (CNP) and Brain Mind Institute (BMI), École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland

⁷Sérotheque Centrale / Biotheque SML, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland

⁸Laboratory of Biological Psychiatry, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

⁹Laboratory of Neuroimaging and Alzheimer's Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy

¹⁰Division of Radiology, Geneva University Hospitals, Geneva, Switzerland

¹¹Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden

¹²Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute

Clinical Neuroscience Institute, King's College London, London, UK

¹³NIHR Biomedical Research Centre for Mental Health and Biomedical Research, Unit for Dementia, South London and Maudsley, NHS Foundation, London, UK

¹⁴Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway

¹⁵Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

¹⁶Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK

¹⁷UK Dementia Research Institute, UCL, London, UK

¹⁸Hong Kong Center for Neurodegenerative Diseases, Hong Kong, People's Republic of China

¹⁹Department of Psychiatry and Neurochemistry, University of Gothenburg, Gothenburg, Sweden

²⁰Division of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland

Acknowledgements The Memory Centre is funded by the following private donors under the supervision of the Private Foundation of Geneva University Hospitals: A.P.R.A. - Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Genève; Fondation Segré, Genève; Race Against Dementia Foundation, London, UK; Fondation Child Care, Genève; Fondation Edmond J. Safra, Genève; Fondation

Minkoff, Genève; Fondazione Agusta, Lugano; McCall Macbain Foundation, Canada; Nicole et René Keller, Genève; Fondation AETAS, Genève. The Clinical Research Center, at Geneva University Hospitals and Faculty of Medicine provides valuable support for regulatory submissions and data management, and the Sérothèque Centrale/Biothèque SML at Geneva University Hospitals for biofluid processing and storage. Competitive research projects have been funded by: H2020, Innovative Medicines Initiative (IMI), IMI2, Swiss National Science Foundation, VELUX Foundation.

Contributors DA drafted the structure of the present work, took care of data analysis, drafted the first version of the work and revised the following versions critically for important intellectual content. SS, FR, VG and GBF contributed to draft the structure of the present work and revised the first version of the work critically for important intellectual content. All authors had full access to all the data in the study, substantially contributed to the interpretation of data for the present work, revised the work critically for important intellectual content, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. DA and GBF accept full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish.

Funding Data analysed in the present work have been collected in the context of research projects supported by the Swiss National Science Foundation: 320030_169876, 320030_185028, and 320030_182772. DA received funding by the Fondation Recherche Alzheimer and the Swiss National Science Foundation (project CRSK-3_196354/1). SS was supported by a grant from the Swiss National Science Foundation (SNSF 320030_185028). AL received funding from the Alzheimer's Association (AACSF-19-617308), and European Union's Horizon 2020 Research and Innovation Program under the Marie Skłodowska-Curie grant agreement #839098. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712 and #101053962), Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C and #ADSF-21-831377-C), the Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme – Neurodegenerative Disease Research (JPND2021-00694), and the UK Dementia Research Institute at UCL (UKDRI-1003). VG was supported by the Swiss National Science Foundation (projects 320030_169876, 320030_185028 and IZSEZO_188355), by the Velux foundation (project 1123), by the Schmidheiny foundation, and by the Aetas foundation. GBF received funding by the EU-EFPIA Innovative Medicines Initiative 2 Joint Undertaking (IMI 2 JU) European Prevention of Alzheimer's Dementia consortium (EPAD, grant agreement number: 115736) and Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952); the Swiss National Science Foundation (COSCODE, grant number: 320030_182772); A.P.R.A. - Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Genève; Fondation Segré, Genève; Ivan Pictet, Genève; Fondazione Agusta, Lugano; Fondation Chmielewski, Genève; VELUX Foundation.

Competing interests HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a cofounder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). VG received financial support for research and/or speaker fees through her institution from Siemens Healthineers, GE Healthcare, Life Molecular Imaging, Cerveau Technologies, Roche, Merck. GBF has received unrestricted grants and support for event organisation from ROCHE Pharmaceuticals; OM Pharma; EISAI Pharmaceuticals; Biogen Pharmaceuticals.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by Geneva Ethics Committee (IDs of the ethics approvals: PB_2016-01346 and 2020_00403). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content

includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Daniele Altomare <http://orcid.org/0000-0003-1905-8993>

Sara Stampacchia <http://orcid.org/0000-0001-9545-3376>

Henrik Zetterberg <http://orcid.org/0000-0003-3930-4354>

REFERENCES

- McKhann G, Drachman D, Folstein M, *et al*. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services Task force on Alzheimer's disease. *Neurology* 1984;34:939–44.
- Jack CR Jr, Bennett DA, Blennow K, *et al*. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. *Neurology* 2016;87:539–47.
- Frisoni GB, Boccardi M, Barkhof F, *et al*. Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. *Lancet Neurol* 2017;16:661–76.
- Altomare D, Caprioglio C, Assal F, *et al*. Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. *Eur J Nucl Med Mol Imaging* 2021;48:2200–11.
- Teunissen CE, Verberk IMW, Thijssen EH, *et al*. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. *Lancet Neurol* 2022;21:66–77.
- Ribaldi F, Chicherio C, Altomare D, *et al*. Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): rationale and study design. *Alzheimers Res Ther* 2021;13:105.
- Albert MS, DeKosky ST, Dickson D, *et al*. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011;7:270–9.
- McKhann GM, Knopman DS, Chertkow H, *et al*. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011;7:263–9.
- Caprioglio C, Garibotto V, Jessen F, *et al*. The clinical use of Alzheimer's disease biomarkers in patients with mild cognitive impairment: a European Alzheimer's disease Consortium survey. *J Alzheimers Dis* 2022;89:535–51.
- Amft M, Ortner M, Eichenlaub U, *et al*. The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort. *Alzheimers Res Ther* 2022;14:60.
- Campbell MR, Ashrafzadeh-Kian S, Petersen RC, *et al*. P-tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status. *Alzheimers Dement (Amst)* 2021;13:e12190.
- Park J-C, Han S-H, Yi D, *et al*. Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease. *Brain* 2019;142:771–86.
- Simoa@ technology | quantex. Available: <https://www.quantex.com/simoa-technology/> [Accessed 22 Jul 2022].
- Karikari TK, Pascoal TA, Ashton NJ, *et al*. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *Lancet Neurol* 2020;19:422–33.
- Ashton NJ, Pascoal TA, Karikari TK, *et al*. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. *Acta Neuropathol* 2021;141:709–24.
- FreeSurfer. Available: <https://surfer.nmr.mgh.harvard.edu/> [Accessed 22 Jul 2022].
- Rhodus-Meester HFM, Benedictus MR, Wattjes MP, *et al*. MRI visual ratings of brain atrophy and white matter hyperintensities across the spectrum of cognitive decline are differently affected by age and diagnosis. *Front Aging Neurosci* 2017;9:117.
- Dodich A, Mendes A, Assal F, *et al*. The A/T/N model applied through imaging biomarkers in a memory clinic. *Eur J Nucl Med Mol Imaging* 2020;47:247–55.
- Guedj E, Varrone A, Boellaard R, *et al*. EANM procedure guidelines for brain PET imaging using [18F] FDG, version 3. *Eur J Nucl Med Mol Imaging* 2022;49:632–51.
- Centiloid project - the global Alzheimer's association interactive network. Available: <https://gain.org/centiloid-project> [Accessed 22 Jul 2022].
- Landau SM, Thomas BA, Thurfjell L, *et al*. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. *Eur J Nucl Med Mol Imaging* 2014;41:1398–407.
- Klunk WE, Koeppe RA, Price JC, *et al*. The centiloid project: standardizing quantitative amyloid plaque estimation by PET. *Alzheimers Dement* 2015;11:1–15.
- Vizamyl - european medicines agency - summary of product characteristics. Available: https://www.ema.europa.eu/en/documents/product-information/vizamyl-epar-product-information_en.pdf [Accessed 13 Oct 2020].
- Amyvid - european medicines agency - summary of product characteristics. Available: https://www.ema.europa.eu/en/documents/product-information/amyvid-epar-product-information_en.pdf [Accessed 13 Oct 2020].

- 25 Mishra S, Gordon BA, Su Y, *et al.* AV-1451 PET imaging of tau pathology in preclinical alzheimer disease: defining a summary measure. *Neuroimage* 2017;161:171–8.
- 26 Fleisher AS, Pontecorvo MJ, Devous MD, *et al.* Positron emission tomography imaging with [¹⁸F]flortaucipir and postmortem assessment of alzheimer disease neuropathologic changes. *JAMA Neurol* 2020;77:829–39.
- 27 Gold G, Bouras C, Kövari E, *et al.* Clinical validity of Braak neuropathological staging in the oldest-old. *Acta Neuropathol* 2000;99:579–82;
- 28 Lowe VJ, Lundt ES, Albertson SM, *et al.* Tau-positron emission tomography correlates with neuropathology findings. *Alzheimers Dement* 2020;16:561–71.
- 29 Sonni I, Lesman Segev OH, Baker SL, *et al.* Evaluation of a visual interpretation method for tau-PET with ¹⁸F-flortaucipir. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* 2020;12:12.
- 30 Landau SM, Harvey D, Madison CM, *et al.* Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. *Neurobiol Aging* 2011;32:1207–18.
- 31 Landau SM, Harvey D, Madison CM, *et al.* Comparing predictors of conversion and decline in mild cognitive impairment. *Neurology* 2010;75:230–8.
- 32 INNOTEST® | fujirebio. Available: <https://www.fujirebio.com/en/products-solutions/innotestr> [Accessed 28 Aug 2022].
- 33 Robin X, Turck N, Hainard A, *et al.* Proc: an open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics* 2011;12:77.
- 34 Verberk IMW, Slot RE, Verfaillie SCJ, *et al.* Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. *Ann Neurol* 2018;84:648–58.
- 35 Garibotto V, Boccardi M, Chiti A, *et al.* Molecular imaging and fluid biomarkers of Alzheimer's disease neuropathology: an opportunity for integrated diagnostics. *Eur J Nucl Med Mol Imaging* 2021;48:2067–9.
- 36 Cullen NC, Janelidze S, Mattsson-Carlgrén N, *et al.* Test-retest variability of plasma biomarkers in alzheimer's disease and its effects on clinical prediction models. *Alzheimers Dement* 2022. 10.1002/alz.12706 [Epub ahead of print 14 Jun 2022].
- 37 Mielke MM, Dage JL, Frank RD, *et al.* Performance of plasma phosphorylated tau 181 and 217 in the community. *Nat Med* 2022;28:1398–405.
- 38 Janelidze S, Stomrud E, Brix B, *et al.* Towards a unified protocol for handling of CSF before β -amyloid measurements. *Alzheimers Res Ther* 2019;11:63.
- 39 Ashton NJ, Leuzy A, Karikari TK, *et al.* The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. *Eur J Nucl Med Mol Imaging* 2021;48:2140–56.
- 40 Ashton NJ, Janelidze S, Al Khleifat A, *et al.* A multicentre validation study of the diagnostic value of plasma neurofilament light. *Nat Commun* 2021;12:3400.
- 41 Altomare D, Collij L, Caprioglio C, *et al.* Description of a european memory clinic cohort undergoing amyloid-PET: the AMYPAD diagnostic and patient management study. *Alzheimers Dement* 2022. 10.1002/alz.12696 [Epub ahead of print 17 Jun 2022].
- 42 Ashton NJ, Suárez-Calvet M, Karikari TK, *et al.* Effects of pre-analytical procedures on blood biomarkers for alzheimer's pathophysiology, glial activation, and neurodegeneration. *Alzheimers Dement (Amst)* 2021;13:e12168.